Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis.
Curr Probl Cancer
; 50: 101076, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38537395
ABSTRACT
PURPOSE:
Selinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM). We sought to quantitatively summarize the selinexor efficacy and safety in RRMM.METHODS:
We searched PubMed, EMBASE, CENTRAL, clinicaltrial.gov, and google scholar, until May 2023, studies about selinexor use in RRMM. The outcome measures of interest were primarily efficacy outcomes, in addition to safety outcomes. Random-effect model analyses were performed, at statistical significance of P<0.05, using the RevMan software.RESULTS:
Meta-analyses of eleven included clinical trials yielded a significant 56.21% overall clinical benefit, 46.91% overall response, 4.89% complete response, 23.41% very good partial response, 24.68% partial response, and 28.06% stable disease rates with selinexor. Due to safety reasons, selinexor caused significant increase in discontinuation rate, 16.80%. Subgroup analyses demonstrated higher efficacy with selinexor plus dexamethasone and proteasome inhibitor combinations than with selinexor alone. The multiple myeloma type, high cytogenetic risk, refractory state, and advanced disease state did not affect performance. Risk of selection, performance, and detection biases were unclear in the included trials.CONCLUSION:
Selinexor led to significant positive responses with an acceptable safety profile in RRMM patients, despite higher rates of safety-related discontinuations. Selinexor-based combinations further enhanced response.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Triazóis
/
Hidrazinas
/
Mieloma Múltiplo
Limite:
Humans
Idioma:
En
Revista:
Curr Probl Cancer
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Qatar